Dr. Reddy's Laboratories

Hyderabad, India Founded: 1984 • Age: 42 yrs Listed Fortune India 500 · #83 India's Most Valuable
Innovative medicines are developed and manufactured globally by the company.
Request Access
Report Incorrect Data
Page last updated

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a publicly listed company based in Hyderabad (India) founded in 1984. Innovative medicines are developed and manufactured globally by the company. The company has 27,535 employees. Dr. Reddy's Laboratories has completed 9 acquisitions, including Betapharm, Cidmus and Habitrol. Its chief executive, as recorded, is Erez Israeli. Its website drreddys.com draws about 119 thousand monthly visits. Its Indian entity Dr.Reddy's Laboratories Ltd reported revenue of ₹35,072 Cr. Dr. Reddy's Laboratories offers products and services including Generic Medicines and Active Pharmaceutical Ingredients. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

Dr. Reddys Laboratories was founded in 1984 in Hyderabad, India, and operates as a multinational pharmaceutical entity. Active pharmaceutical ingredients, generics, branded generics, biosimilars, and over-the-counter products are produced across therapeutic areas such as gastrointestinal, cardiovascular, oncology, anti-infectives, pediatrics, and dermatology. Operations span global markets with a focus on drug development and manufacturing.

Dr. Reddy's Laboratories is ranked #83 on the Fortune India 500 (2025).

Recognitions & Rankings of Dr. Reddy's Laboratories

Fortune India 500 2025 edition
Rank#83
Total income
₹34,308 Cr
Profit
₹5,655 Cr
Last year #85
India's Most Valuable Companies 2025 edition · Source: Hurun India
Valuation
₹1,10,420 Cr
2024 #61 2023 #47 2022 #54
  • Headquarters Hyderabad, India
  • Employees 27,535
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website drreddys.com
  • Social LinkedIn X Facebook
  • Legal Name Dr. Reddy's Laboratories Ltd.
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹1,15,017 Cr

    DRREDDY · NSE

  • Share Price
    ₹1,386.60

    +0.70% today

  • Revenue
    ₹33,700 Cr

    FY 2025-26 · +3.2% YoY

  • EBITDA
    ₹6,454 Cr

    Margin 19.1%

  • Net Profit
    ₹4,007 Cr

    FY 2025-26 · -27.8% YoY

  • P/E (TTM)
    41.3x

    P/B 3.0x

  • ROE
    11.6%

    ROCE 13.7%

  • Debt / Equity
    0.17

    Interest cover 8.5x

  • Latest Funding Round
    $3.45M (USD), Post-IPO

    Feb 2025

  • Investors
    Digit Insurance

    & 1 more

  • Employee Count
    27,535
  • Investments & Acquisitions
    Betapharm

    & 8 more

Products & Services of Dr. Reddy's Laboratories

Dr. Reddy's Laboratories offers a comprehensive portfolio of products and services, including Generic Medicines and Active Pharmaceutical Ingredients.

Generic Medicines
Pharmaceutical Products

Generic medicines are produced for treating common health conditions

Active Pharmaceutical Ingredients
Chemical Products

Active pharmaceutical ingredients are supplied for use in drug formulations

Funding Insights of Dr. Reddy's Laboratories

  • Total Rounds 3
  • Last Round Post-IPO — $3.45M
  • First Round $354,236

    (Oct 2016)

  • Investors Count 2

All 3 funding rounds of Dr. Reddys Laboratories with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2025$3.45MPost-IPO––
Digit Insurance
Jun 2022Post-IPO––
Gates Foundation
Oct 2016$354,236Grant––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Dr. Reddy's Laboratories

Dr. Reddy's Laboratories has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Digit Insurance and Gates Foundation.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Gates Foundation
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
Digit Insurance
General and life insurance products are provided across multiple categories.
2016godigit.comBengaluru, India
Premium access

Investor details for Dr. Reddys Laboratories

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Dr.Reddy's Laboratories Ltd (Dr. Reddy's Laboratories)

Dr.Reddy's Laboratories Ltd is the primary company behind Dr. Reddy's Laboratories. The board of Dr.Reddy's Laboratories Ltd currently have 11 directors; the longest-serving is Venkateswara Prasad Gunupati, appointed in 1986. 24 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Venkateswara Prasad Gunupati
DIN 00057433
Managing Director08 Apr 198640 yrs 7 moDr.Reddy's Laboratories Ltd
Satish Reddy Kallam
DIN 00129701
Whole-time director18 Jan 199333 yrs 9 moDr.Reddy's Laboratories Ltd
Leo Puri
DIN 01764813
Director25 Oct 20188 yrsDr.Reddy's Laboratories Ltd
Shikha Sanjaya Sharma
DIN 00043265
Director31 Jan 20197 yrs 9 moDr.Reddy's Laboratories Ltd
Kodumudi Pranatharthiharan Krishnan
DIN 01099097
Director07 Jan 20224 yrs 10 moDr.Reddy's Laboratories Ltd
Penny Chan Wan
DIN 09479493
Director28 Jan 20224 yrs 9 moDr.Reddy's Laboratories Ltd
Arun Madhavan Kumar
DIN 09665138
Director01 Aug 20224 yrs 3 moDr.Reddy's Laboratories Ltd
Claudio Dr Albrecht
DIN 10109819
Director10 May 20233 yrs 6 moDr.Reddy's Laboratories Ltd
Alpna Hansraj Seth
DIN 01183914
Director19 Sep 20233 yrs 1 moDr.Reddy's Laboratories Ltd
Sanjiv Soshil Mehta
DIN 06699923
Director29 Dec 20232 yrs 10 moDr.Reddy's Laboratories Ltd
Srikanth Velamakanni
DIN 01722758
Director01 Jul 20264 moDr.Reddy's Laboratories Ltd

People of Dr. Reddy's Laboratories

663 people are tracked at Dr. Reddy's Laboratories (281 in leadership, 8 in board & advisors, 374 in team); the tracked headcount is 27,535.

NameRoleGroup
Erez Israeli
CEOLeadership
Sachin Gaur
Global Head - Capability, Change, Org. And Leadership DevelopmentLeadership
Abigail Amato Blunda
Senior Director, People & Organization Partner - NALeadership
Jodi Evenson
Director, Sales - WestLeadership
M V Ramana
CEO- Branded Markets (India and Emerging Markets)Leadership
Sandeep Dava
Talent Management PartnerLeadership
G V Prasad
Co-Chairman & CEOLeadership
Rami Reddy Dontireddy
Head Engineering And MaintenanceLeadership
Dr Raja Mohamed
Team Lead (associate Director)Leadership
Amarendra Duvvala
Business Partner - SFE AnalyticsLeadership
Dr. Satheeshkumar Sriharan
Group Country Head-china Mainland & TaiwanLeadership
Sandeep Khandelwal
Head - India Subcontinent BusinessLeadership
Joe Garbini
Senior Director,idn Reg. Mgr. - WestLeadership
Ben Kleppel
Director, 3pl Operations, Warehousing, & LogisticsLeadership
Axay Pithava
Head Of Marketing - Dental Business (oral Care)Leadership
Nisha Shah
Director Talent AcquisitionLeadership
Swarna R.
VP , Head HR - North AmericaLeadership
Br Reddy
Sr.vice PresidentLeadership
Kathryn Healy
Director, OTC Brand MarketingLeadership
Navjot Dhar
HR Head RussiaLeadership

643 more people are available in the full profile.

Premium access

Complete people profiles for Dr. Reddy's Laboratories

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a publicly listed company on the NSE with ticker symbol DRREDDY in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date05 Dec 2003
  • Listed onFRA: RDDA
  • Listed entityDr. Reddy's Laboratories Ltd.
  • Exchange sectorHealth technology
  • ISININE089A01031
  • Share price₹1,216.00 (-1.94% on the day) · 2026-10-14
  • Market capitalisation₹103,420 Cr
  • Price to earnings30.6
  • EPS (diluted, trailing year)₹39.68
  • Dividend yield0.65%
  • Volume (last session)1,615,560

Financials of Dr. Reddy's Laboratories

Exchange-reported figures of Dr.Reddy's Laboratories Ltd, the listed company behind Dr. Reddy's Laboratories (NSE: DRREDDY).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹33,700 Cr
+3.2% YoY
EBITDA
₹6,454 Cr
-24.5% YoY
Profit After Tax
₹4,007 Cr
-27.8% YoY
Net Worth
₹37,892 Cr
+12.9% YoY
Total Assets
₹46,343 Cr
+19.2% YoY
Total Debt
₹7,734 Cr
+65.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue33,70032,64428,01124,67021,54519,04817,517
Revenue growth+3.2%+16.5%+13.5%+14.5%+13.1%+8.7%-
EBITDA6,4548,5477,9336,3493,7683,8702,470
EBITDA margin+19.2%+26.2%+28.3%+25.7%+17.5%+20.3%+14.1%
Profit before tax5,3937,6807,2016,0483,0612,8841,886
Net profit4,0075,5485,5124,5982,1111,9542,030
Net profit margin+11.9%+17.0%+19.7%+18.6%+9.8%+10.3%+11.6%
EPS (₹)50.2567.81334.41270.55131.16117.28121.90
Balance sheet
Total assets46,34338,87930,59524,85622,79020,88518,089
Net worth37,89233,55028,25523,28619,21217,64215,599
Total debt7,7344,6772,0021,3473,3843,0312,210
Cash & bank3,3492,4601,7281,7302,4192,079205
Net working capital16,12212,54412,2158,6238,8097,4695,096
Cash flow
Cash from operations5,6744,6434,5435,8882,8113,5702,984
Cash from investing(6,425)(5,785)(4,034)(4,109)(2,565)(2,255)(495)
Cash from financing8291,891(376)(2,686)(242)(29.80)(2,516)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue8,6988,1007,5468,7538,8288,5728,5288,381
Revenue growth (YoY)-1.5%-5.5%-11.5%+4.4%+9.8%+11.4%--
Other income156356480271330290528154
EBITDA1,7238603821,8882,0102,1741,9982,273
EBITDA margin+19.9%+10.7%+5.1%+21.6%+22.8%+25.4%+23.5%+27.2%
Depreciation527537557521505476455471
Interest12512610694.4090.7083.0065.6081.70
Profit before tax1,2285532001,5431,7451,9052,0051,874
Tax314118(21.60)354408495418470
Net profit9134362211,1901,3371,4101,5871,404
EPS (₹)11.095.332.6514.5216.1817.0219.1016.94
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20,53323,11519,48416,96214,40513,34911,850
Revenue growth-11.2%+18.6%+14.9%+17.8%+7.9%+12.7%-
EBITDA3,9177,3825,9264,2152,5943,1372,870
EBITDA margin+19.1%+31.9%+30.4%+24.9%+18.0%+23.5%+24.2%
Profit before tax4,2517,2365,7913,8662,2243,0562,776
Net profit3,0635,3814,2842,6291,6291,8492,949
Net profit margin+14.9%+23.3%+22.0%+15.5%+11.3%+13.9%+24.9%
EPS (₹)38.5664.14260.31156.8397.55131.39176.76
Balance sheet
Total assets37,35732,54025,14820,61820,63618,26616,733
Net worth31,36628,85724,24120,47418,33616,98415,192
Total debt5,7373,49379350.802,2051,2141,457
Cash & bank1,9589771,2176462,0301,64639.20
Net working capital9,6348,3858,9035,0737,7206,3245,245
Cash flow
Cash from operations4,6604,2253,4505,0531,3393,5141,839
Cash from investing(5,760)(5,697)(3,429)(3,403)(1,990)(1,454)(1,689)
Cash from financing1,1171,59168.10(2,697)506(794)(224)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5,5735,1373,8224,2834,6197,8105,5635,015
Revenue growth (YoY)+20.7%-34.2%-31.3%-14.6%-31.0%+33.7%--
Other income217440567360364398414235
Total expenses4,4784,6894,3224,1834,1383,9724,1203,823
EBITDA1,095447(500)99.604803,8371,4431,192
EBITDA margin+19.7%+8.7%-13.1%+2.3%+10.4%+49.3%+26.0%+23.9%
Depreciation334318318314295280264265
Interest77.0073.1054.3041.4033.4019.2031.1043.30
Profit before tax901497(306)1045163,9361,5621,119
Tax20692.30(86.10)13.60129975361270

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue8,6988,1007,5468,7538,8288,5728,5288,381
Revenue growth (YoY)-1.5%-5.5%-11.5%+4.4%+9.8%+11.4%--
Other income156356480271330290528154
EBITDA1,7238603821,8882,0102,1741,9982,273
EBITDA margin+19.9%+10.7%+5.1%+21.6%+22.8%+25.4%+23.5%+27.2%
Depreciation527537557521505476455471
Interest12512610694.4090.7083.0065.6081.70
Profit before tax1,2285532001,5431,7451,9052,0051,874
Tax314118(21.60)354408495418470
Net profit9134362211,1901,3371,4101,5871,404
EPS (₹)11.095.332.6514.5216.1817.0219.1016.94
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue33,70032,64428,01124,67021,54519,04817,517
Revenue growth+3.2%+16.5%+13.5%+14.5%+13.1%+8.7%-
Other income1,3721,1199091,092555339677
Total expenses27,24724,09720,07818,32117,77815,17815,047
Employee cost5,9915,5805,0304,6473,8863,6303,380
EBITDA6,4548,5477,9336,3493,7683,8702,470
EBITDA margin+19.2%+26.2%+28.3%+25.7%+17.5%+20.3%+14.1%
Depreciation2,0591,7041,4701,2501,1651,2291,163
Interest37428317114395.8097.0098.30
Profit before tax5,3937,6807,2016,0483,0612,8841,886
Tax1,2351,9541,6231,541879932(140)
Net profit4,0075,5485,5124,5982,1111,9542,030
Net profit margin+11.9%+17.0%+19.7%+18.6%+9.8%+10.3%+11.6%
EPS (₹)50.2567.81334.41270.55131.16117.28121.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital83.5083.4083.4083.3083.2083.2083.10
Reserves & surplus37,99033,69328,17123,33019,28917,75515,616
Shareholders' funds (net worth)37,89233,55028,25523,28619,21217,64215,599
Minority interest3393780.000.000.000.000.00
Secured loans0.000.000.000.000.000.00179
Unsecured loans7,7344,6772,0021,3473,3843,0312,032
Total debt7,7344,6772,0021,3473,3843,0312,210
Total liabilities46,34338,87930,59524,85622,79020,88518,089
Assets
Gross block43,85436,76028,06225,56723,09618,55616,108
Net block22,06318,22610,4269,2198,1228,2066,850
Capital work in progress1,4602,4661,4191,0301,2931,5651,535
Investments5,2854,0514,9304,9862,6162,2122,678
Inventories7,6537,1086,3554,8675,0884,5413,507
Sundry debtors10,1239,0428,0307,2486,6764,9645,028
Cash & bank balances3,3492,4601,7281,7302,4192,079205
Loans & advances5,2303,0774,2882,1301,5811,5881,491
Total current assets26,35621,68720,40015,97615,76513,17210,230
Total current liabilities10,2349,1448,1857,3536,9565,7035,134
Net working capital16,12212,54412,2158,6238,8097,4695,096
Total assets46,34338,87930,59524,85622,79020,88518,089
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,4597115781,4851,482196223
Net cash from operating activities5,6744,6434,5435,8882,8113,5702,984
Net cash from investing activities(6,425)(5,785)(4,034)(4,109)(2,565)(2,255)(495)
Net cash from financing activities8291,891(376)(2,686)(242)(29.80)(2,516)
Net change in cash77.50749133(907)3.201,286(26.60)
Closing cash3,3492,4601,7281,7302,4192,079205
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.2%+16.5%+13.5%+14.5%+13.1%+8.7%-
EBITDA growth-24.5%+7.7%+25.0%+68.5%-2.6%+56.7%-
PBT growth-29.8%+6.6%+19.1%+97.6%+6.2%+52.9%-19.3%
Net income growth-27.8%+0.7%+19.9%+117.8%+8.0%-3.7%-
Revenue CAGR (3Y)+11.0%+14.9%+13.7%+12.1%+11.7%+10.1%+7.3%
EBITDA CAGR (3Y)+0.6%+31.4%+27.0%+37.0%+5.8%+18.1%-0.0%
Profitability & leverage
Net income margin+12.3%+17.5%+19.9%+18.3%+10.1%+10.3%+11.6%
Return on capital employed+13.7%+23.1%+26.6%+26.0%+14.5%+15.3%+11.0%
Return on net worth+11.6%+18.5%+21.6%+21.2%+11.8%+11.7%+13.7%
Debt / equity0.170.110.060.110.170.160.20
Long-term debt / equity0.030.020.010.020.030.020.08
Interest cover8.514.132.652.803.683.677.52
Efficiency & per share
Fixed asset turnover0.841.011.041.011.031.101.13
Inventory turnover4.574.854.994.964.474.735.10
Debtors turnover3.523.823.673.543.703.813.89
EPS (₹)50.2567.81334.41270.55131.16117.28121.90
Dividend per share (₹)8.008.0040.0040.0030.0025.0025.00
Book value per share (₹)455.96404.991,693.931,405.341,164.211,072.02944.61
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5,5735,1373,8224,2834,6197,8105,5635,015
Revenue growth (YoY)+20.7%-34.2%-31.3%-14.6%-31.0%+33.7%--
Other income217440567360364398414235
Total expenses4,4784,6894,3224,1834,1383,9724,1203,823
EBITDA1,095447(500)99.604803,8371,4431,192
EBITDA margin+19.7%+8.7%-13.1%+2.3%+10.4%+49.3%+26.0%+23.9%
Depreciation334318318314295280264265
Interest77.0073.1054.3041.4033.4019.2031.1043.30
Profit before tax901497(306)1045163,9361,5621,119
Tax20692.30(86.10)13.60129975361270
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20,53323,11519,48416,96214,40513,34911,850
Revenue growth-11.2%+18.6%+14.9%+17.8%+7.9%+12.7%-
Other income1,6901,003862591482801743
Total expenses16,61515,73413,55712,74811,81110,2128,981
Employee cost3,5503,2883,0862,8332,4352,2702,030
EBITDA3,9177,3825,9264,2152,5943,1372,870
EBITDA margin+19.1%+31.9%+30.4%+24.9%+18.0%+23.5%+24.2%
Depreciation1,2071,039976923814835789
Interest14811021.8016.9038.0046.7047.80
Profit before tax4,2517,2365,7913,8662,2243,0562,776
Tax1,0321,8861,4491,253601870(162)
Net profit3,0635,3814,2842,6291,6291,8492,949
Net profit margin+14.9%+23.3%+22.0%+15.5%+11.3%+13.9%+24.9%
EPS (₹)38.5664.14260.31156.8397.55131.39176.76
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital83.5083.4083.4083.3083.2083.2083.10
Reserves & surplus31,46429,00024,15720,51818,41317,09715,209
Shareholders' funds (net worth)31,36628,85724,24120,47418,33616,98415,192
Secured loans0.000.000.000.000.000.0019.30
Unsecured loans5,7373,49379350.802,2051,2141,438
Total debt5,7373,49379350.802,2051,2141,457
Total liabilities37,35732,54025,14820,61820,63618,26616,733
Assets
Gross block21,34417,71516,29715,13713,34912,34510,216
Net block10,7308,2327,5897,1956,1505,8444,434
Capital work in progress1,3692,1971,2119241,200901412
Investments15,59513,1947,3217,4404,9374,6495,486
Inventories4,9564,5764,0193,0433,3482,8202,190
Sundry debtors4,1195,9594,6244,2894,9454,0804,639
Cash & bank balances1,9589771,2176462,0301,64639.20
Loans & advances4,2582,1083,8381,5131,2551,1411,120
Total current assets15,29013,62013,6989,49011,5799,6877,988
Total current liabilities5,6565,2354,7954,4183,8593,3642,743
Net working capital9,6348,3858,9035,0737,7206,3245,245
Total assets37,35732,54025,14820,61820,63618,26616,733
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3202011121,1601,30539.10113
Net cash from operating activities4,6604,2253,4505,0531,3393,5141,839
Net cash from investing activities(5,760)(5,697)(3,429)(3,403)(1,990)(1,454)(1,689)
Net cash from financing activities1,1171,59168.10(2,697)506(794)(224)
Net change in cash17.8011889.10(1,047)(146)1,266(74.10)
Closing cash1,9589771,2176462,0301,64639.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-11.2%+18.6%+14.9%+17.8%+7.9%+12.7%-
EBITDA growth-46.9%+24.6%+40.6%+62.5%-17.3%+9.3%-
PBT growth-41.3%+24.9%+49.8%+73.9%-27.2%+10.1%+63.2%
Net income growth-43.1%+25.6%+63.0%+61.4%-11.9%-37.3%-
Revenue CAGR (3Y)+6.6%+17.1%+13.4%+12.7%+10.7%+12.6%+6.8%
EBITDA CAGR (3Y)-2.4%+41.7%+23.6%+13.7%+4.1%+33.1%+18.0%
Profitability & leverage
Net income margin+15.7%+23.1%+22.3%+15.4%+11.3%+16.4%+24.8%
Return on capital employed+12.6%+25.5%+25.4%+18.8%+11.6%+15.0%+18.5%
Return on net worth+10.7%+20.2%+19.4%+13.5%+9.2%+11.5%+21.1%
Debt / equity0.150.080.020.060.100.080.09
Long-term debt / equity0.010.000.000.000.000.000.01
Interest cover5.471.730.440.512.142.032.30
Efficiency & per share
Fixed asset turnover1.051.361.241.191.121.181.19
Inventory turnover4.315.385.525.314.675.335.63
Debtors turnover4.074.374.373.673.193.062.84
EPS (₹)38.5664.14260.31156.8397.55131.39176.76
Dividend per share (₹)8.008.0040.0040.0030.0025.0025.00
Book value per share (₹)377.81348.721,453.291,236.561,111.561,032.48920.13

Investments & Acquisitions by Dr. Reddy's Laboratories

Dr. Reddy's Laboratories has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Betapharm, Cidmus and Habitrol.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Northstar Switzerland
Provider of business consulting services
Nyon, Switzerland2023Jun 2024$579.45M
MenoLabs
Probiotic supplements for menopause symptoms are developed.
menolabs.comTucson, United States2019Dec 2023$3M
Mayne Pharma
Drug delivery systems are developed and marketed globally through partnerships.
maynepharma.comAdelaide, Australia1845Mar 2023••••
Cidmus
Manufacturer of drugs
0Apr 2022$61M
Nimbus Health
Cannabinoid-based drugs are developed and branded by Nimbus Health.
nimbus.healthOffenbach, Germany2018Feb 2022••••
Habitrol
Nicotine patches and lozenges are manufactured for smoking cessation aid.
habitrol.comPrinceton, United States1999Dec 2014••••
OctoPlus
Company specializing in formulation and process development of complex injectables
octoplus.nlLeiden, Netherlands1995Oct 2012$36M
Betapharm
Prescription and OTC pharmaceuticals focused on palliative care are developed.
betapharm.deAugsburg, Germany1993Feb 2006$570M
Trigenesis Therapeutics
Proprietary drug delivery platforms are developed for dermatology drugs.
trigenesistx.comPhiladelphia, United States2003May 2004$11M
Premium access

Complete acquisition details for Dr. Reddys Laboratories

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Dr. Reddy's Laboratories

13 dated milestones of Dr. Reddy's Laboratories across 41 years, from founding to its latest funding, stage changes and deals.

  1. Founded Dr. Reddy's Laboratories is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Trigenesis Therapeutics.
  4. Acquisition Acquires Betapharm.
  5. Acquisition Acquires OctoPlus.
  6. Acquisition Acquires Habitrol.
  7. Funding First funding round of $354K.
  8. Acquisition Acquires Nimbus Health.
  9. Acquisition Acquires Cidmus.
  10. Acquisition Acquires Mayne Pharma.
  11. Acquisition Acquires MenoLabs.
  12. Acquisition Acquires Northstar Switzerland.
  13. Funding Latest funding round, Post-IPO, of $3.4M.

Web traffic of Dr. Reddy's Laboratories

The website of Dr. Reddy's Laboratories (drreddys.com) receives about 118.8K visits a month and ranks #308,607 among all websites worldwide, #10,770 in Health.

  • Monthly visits
    118.8K

    ▼ 9.4% vs previous month

  • Unique visitors
    65K

    per month

  • Global rank
    #308,607

    among all websites

  • Category rank
    #10,770

    Health · Health

Similar websites

Websites whose visitors overlap most with Dr. Reddy's Laboratories. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Cipla
cipla.com
100%
200.9K#203,362View details
Sun Pharma
sunpharma.com
99%
216K#177,160View details
Aurobindo Pharma
aurobindo.com
82%
24.4K#1,029,164View details
Ranbaxy Laboratories
ranbaxy.com
82%
View details
Abbott
abbott.com
72%
917.2K#65,577View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Dr. Reddy's Laboratories

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Dr. Reddy's Laboratories (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Dr. Reddy's Laboratories

Dr. Reddy's Labs: Gains Approval For Generic Semaglutide Injection In Brazil; Targets Adults With Uncontrolled Type 2 Diabetes; Launch In Collaboration With Aché Planned.
Exchange Update • 7 days ago
Dr Reddy's: JPMorgan on Dr Reddy's Upgrades to Neutral, Target Price ₹1,270; Q2 revenue missed estimates, but adjusted core margin of 19.5% beat by 160bps due to lower R&D, controlled SG&A and weaker PSAI revenue. Semaglutide execution and abatacept approval remain uncertain, while valuations appear full.
Exchange Update • 17 days ago
Dr Reddy's: Kotak Institutional Equities on Dr Reddy's Maintains Reduce, Target Price ₹1,220; adjusted EBITDA margin recovered to 19.1%, beating estimates by 440bps, aided by launches, better mix, cost efficiencies and forex. Semaglutide supplies are expected to resume in November 2026 and H2 margins may exceed 20%, but full valuations limit upside.
Exchange Update • 17 days ago
Dr Reddy's: Nomura on Dr Reddy's Maintains Buy, Target Price ₹1,730; Q2 EBITDA beat was driven by cost efficiencies and product mix, with management expecting margins above 20%. Semaglutide relaunch and abatacept approval are key catalysts; stock trades at 16x FY29F EPS.
Exchange Update • 17 days ago
Dr Reddy's: Citi on Dr Reddy's Maintains Buy, Target Price ₹1,510; adjusted EBITDA of ₹16.4bn was around 40% above estimates, with margins recovering to 19.1% on better mix, operating leverage and cost efficiencies. Management expects strength to continue in H2, with semaglutide and abatacept timelines on track; raises FY27–29 EPS by 11%/7%/2%.
Exchange Update • 17 days ago
Dr Reddy's: HSBC on Dr Reddy's Maintains Buy, Target Price ₹1,375; higher branded-segment contribution and US launches improved Q2 gross margins. Semaglutide commercial supplies are expected to resume in November 2026, while the relaunch and FDA approval of abatacept remain key catalysts.
Exchange Update • 17 days ago
Dr. Reddy's: Lab Maintains FY27 EBITDA Margin Forecast Above 20%, Reports Q2 Margins At 20.6%
Exchange Update • 19 days ago
Dr. Reddy's: Semaglutide Relaunch Remains On Track For November 2026, With FY27 Volume Guidance Of 6 - 7 Million Pens Maintained.
Exchange Update • 19 days ago
Dr. Reddy's: Lowers FY27 Capital Expenditure To ₹1,600–1,700 Crore From ₹1,800 Crore Because Of Project Timing Adjustments.
Exchange Update • 19 days ago
DRREDDY: Q2 REVENUE 86.98B RUPEES VS 88.28B (YOY)
Exchange Update • 20 days ago
Premium access

Complete news archive for Dr. Reddys Laboratories

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Dr. Reddy's Laboratories on our blog

Frequently Asked Questions about Dr. Reddy's Laboratories

Dr. Reddy's Laboratories was founded in 1984 and raised its 1st funding round 32 years after it was founded.

Dr. Reddy's Laboratories is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Erez Israeli is the CEO of Dr. Reddy's Laboratories, as recorded in our data.

Dr. Reddy's Laboratories has 27,535 employees.

The primary company behind Dr. Reddy's Laboratories, Dr.Reddy's Laboratories Ltd, reported revenue of ₹35,072 Cr for FY 2026, up 3% year on year.

Dr. Reddys Laboratories was founded in 1984 in Hyderabad, India, and operates as a multinational pharmaceutical entity. Active pharmaceutical ingredients, generics, branded generics, biosimilars, and over-the-counter products are produced across therapeutic areas such as gastrointestinal, cardiovascular, oncology, anti-infectives, pediatrics, and dermatology. Operations span global markets with a focus on drug development and manufacturing.

Dr. Reddy's Laboratories offers Generic Medicines and Active Pharmaceutical Ingredients.

Yes, Dr. Reddy's Laboratories is publicly traded on NSE under the ticker symbol DRREDDY.

Dr. Reddy's Laboratories has made 9 acquisitions, including Betapharm, Cidmus, and Habitrol.

Dr. Reddy's Laboratories has 2 investors. Key investors include Digit Insurance, and Gates Foundation.

Dr. Reddy's Laboratories operates through Dr.Reddy's Laboratories Ltd.

The legal entities of Dr. Reddy's Laboratories currently have 14 directors, including Leo Puri, Shikha Sanjaya Sharma, Penny Chan Wan and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available